ArticleFrontiers in oncology2026

Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison.

Luna Del Bono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.